|
| |
BID
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18173728 |
activation of Bid is required for inducing apoptosis in this experimental model |
| 17534194 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18166654 |
We conclude that unconventional ubiquitination and proteasome-dependent degradation of tBid-N is required to unleash the proapoptotic activity of tBid-C. |
| 18089817 |
BH3 profiling reveals that mitochondrial BCL-2 is primed by death signals after egf receptor inhibition in lung cancer cells. |
| 17549073 |
Existence of Bid activation pathways in eosinophils other than those mediated by the classic initiator caspases. |
| 17855051 |
Bax translocation by UV irradiation is a Bid-independent event and inhibited by overexpression of Bcl-x(L). |
| 16077201 |
Cathepsin B substrate, BID, serves as molecular switch between apotosis and autophagy in camptothecin treated breast cancer cells. |
| 17431792 |
Bid cleavage occurs prior to the activation of caspase-8 during TRAIL-mediated apoptosis in U2OS cells |
| 17635912 |
mitochondrial TOM complex is required for tBid/Bax-induced cytochrome c release |
| 17226776 |
These findings indicate that phosphorylation of PLS3 by PKC-delta induces PLS3 activation to facilitate mitochondrial targeting of tBid and apoptosis. | →View more information from publications. |
Recent Publications on BID: |  |
Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer.
OBJECTIVE: In this study, we compared the pharmacokinetic profiles of... | 3rd November, 2009
| 1 Cancer Metastasis Research Center, Yonsei University College of
| Jpn J Clin Oncol. 2009 Oct 31.
DOI Direct Link |
A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis.
CP-690,550, a selective inhibitor of the Janus kinase family, is being... | 3rd November, 2009
| Inc.
| J Clin Pharmacol. 2009 Oct 30.
DOI Direct Link |
Response to budesonide among atopic and non-atopic infants/preschoolers with recurrent wheezing.
BACKGROUND: The treatment in non-atopic young children with recurrent... | 31st October, 2009
| Department of Pediatrics, Universidad de Antofagasta, Antofagasta, Chile.
| Allergol Immunopathol (Madr). 2009 Oct 27.
DOI Direct Link |
A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.
Coumarin derivative RKS262 belongs to a new class of potential anti-tumor... | 30th October, 2009
| Molecular Therapeutics Laboratory, Program in Women's Oncology, Department
| Invest New Drugs. 2009 Oct 29.
DOI Direct Link |
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs with pimavanserin (ACP 103), a 5-hydroxytryptamine2A receptor inverse agonist.
Sub-chronic administration of the NMDA receptor antagonist, phencyclidine... | 30th October, 2009
| 1 Vanderbilt Medical Center;
| J Pharmacol Exp Ther. 2009 Oct 28.
DOI Direct Link |
→View more research publications. |
Press Releases on BID:
|
 |
| Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA |
13th November, 2009 |
Karolinska Development AB |
STOCKHOLM, November 13 /PRNewswire/ -- Axelar AB today announced that
promising data from the ongoing Phase I/II clinical trial concerning their
lead anticancer product AXL1717, an insulin-like
|
| INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227 |
3rd November, 2009 |
Pharmasset, Inc. |
BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc (Nasdaq: VRUS) and InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient cohorts of the INFORM-1 trial, an
|
| Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society |
27th October, 2009 |
Orexigen Therapeutics, Inc. |
-- Obese patients on Contrave demonstrated significant improvements in
important markers of cardiometabolic risk including waist circumference,
HDL and triglycerides
|
| Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk |
24th October, 2009 |
Orexigen Therapeutics, Inc. |
-- There was no evidence of increased abuse liability.
"These data show that Contrave provides obese patients with meaningful reduction in weight
|
| Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 |
24th September, 2009 |
Amylin Pharmaceuticals, Inc. |
-- Poster: Presentation #795, Oct. 1, 12:45-1:45 p.m. CEST "Changes in
Adipokines in Type 2 Diabetic Patients Treated with Exenatide versus
Glimepiride on Metformin
|
BID results (if any) from reagent suppliers | 
|
Bid antibody (ab2388) | Abcam
Rabbit polyclonal to Bid. Bid, a BH3 domain containing proapoptotic Bcl2 family member, is localized in the cytosolic fraction of cells as an inactive ...
http://www.abcam.com/Bid-antibody-ab2388.html...
|
 |
BID Antibody (Mouse Specific) #2003
The BH3 domain-only protein, BID, a death agonist member of the Bcl-2/Bcl-xL family (1), is localized in the cytosolic fraction of cells as an inactive ...
http://www.cellsignal.com/products/2003.html...
|
 |
The Abcam catalog
Bid antibodies. ... Bid antibody. IP, WB, IHC-Fr. Rabbit polyclonal ... Bid antibody [Y8]. Flow Cyt, IP, WB, ICC/IF, IHC-P ...
http://www.abcam.com/index.html?t=49106&pt=1&c=299...
|
 |
BID Antibody (Human Specific) #2002
BID Antibody (Human Specific) detects endogenous levels of both the full length (22 kDa) and cleaved large fragment (15 kDa) of human BID. ...
http://www.cellsignal.com/products/2002.html...
|
 |
BID Antibody / BID Antibodies
BID Antibody / BID Antibodies. ... BID specific siRNA, sHRNA Plasmid and shRNA Lentiviral Particles gene silencers are also available. ...
http://www.scbt.com/table-bid.html...
|
 |
BID Antibody
Specific antibody for the gene product of BID, the protein BH3 interacting domain death agonist. Validated for specificity by gene-silencing with siRNA ...
http://www.piercenet.com/products/browse.cfm?fldID=7FC75E6B-...
|
 |
p-BID (Ser 65) Antibody sc-130180
rabbit polyclonal IgG, 100µg/ml; recommended for detection of Ser 65 phosphorylated BID of human origin by WB, IP, IF, IHC(P) and ELISA ...
http://www.scbt.com/datasheet-130180-p-bid-ser-65-antibody.h...
|
 |
Search Bioportfolio and other Life Science Sites for BID,
or search for BID on BioPortfolio's antibody search engine.
This page has been viewed 524 times
Recent Search Terms used to find this page: interacting with death | BH3 interactive domain | Mitochondria-mediated tumstatin peptide-induced HepG2 cell apoptosis | BH3 gene | hepG2 abcam bcl 2 | t-bid antibody | bh3 profiling us patent | interacting domain | bid suggest link.html | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
